NASDAQ: NRIX

Gilead Sciences (NASDAQ: GILD) has announced a two-year extension of its 2019 collaboration with Nurix Therapeutics (NASDAQ: NRIX) focused on the discovery, development, and commercialization of targeted protein degradation therapies. As part of the agreement, Nurix will receive a USD 15 million extension fee for identifying novel agents that induce…